- Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
- KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
- Kazia announces presentation of new data at AACR Annual Meeting
Key statistics
On Tuesday, Kazia Therapeutics Ltd (KZIA:NAQ) closed at 0.2749, 47.32% above the 52 week low of 0.1866 set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.271 |
---|---|
High | 0.29 |
Low | 0.2611 |
Bid | 0.270 |
Offer | 0.29 |
Previous close | 0.2793 |
Average volume | 111.61k |
---|---|
Shares outstanding | 13.18m |
Free float | 777.07k |
P/E (TTM) | -- |
Market cap | 7.39m USD |
EPS (TTM) | -0.8256 USD |
Data delayed at least 15 minutes, as of May 28 2024 20:59 BST.
More ▼